Pressure-dependent fouling behavior during sterile filtration of mRNA-containing lipid nanoparticles

被引:17
作者
Messerian, Kevork Oliver [1 ]
Zverev, Anton [2 ]
Kramarczyk, Jack F. [2 ]
Zydney, Andrew L. [1 ]
机构
[1] Penn State Univ, Dept Chem Engn, 404 Chem & Biomed Engn Bldg, University Pk, PA 16802 USA
[2] Moderna Inc, Cambridge, MA USA
关键词
bioprocessing; fouling; lipid nanoparticle (LNP); mRNA vaccine; sterile filtration; VACCINES; THERAPEUTICS; CHALLENGES; LIPOSOMES; BLOCKING; MODEL;
D O I
10.1002/bit.28200
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The COVID-19 pandemic has generated growing interest in the development of mRNA-based vaccines and therapeutics. However, the size and properties of the lipid nanoparticles (LNPs) used to deliver the nucleic acids can lead to unique phenomena during manufacturing that are not typical of other biologics. The objective of this study was to develop a more fundamental understanding of the factors controlling the performance of sterile filtration of mRNA-LNPs. Experimental filtration studies were performed with a Moderna mRNA-LNP solution using a commercially available dual-layer polyethersulfone sterile filter, the Sartopore 2 XLG. Unexpectedly, increasing the transmembrane pressure (TMP) from 2 to 20 psi provided more than a twofold increase in filter capacity. Also surprisingly, the effective resistance of the fouled filter decreased with increasing TMP, in contrast to the pressure-independent behavior expected for an incompressible media and the increase in resistance typically seen for a compressible fouling deposit. The mRNA-LNPs appear to foul the dual-layer filter by blocking the pores in the downstream sterilizing-grade membrane layer, as demonstrated both by scanning electron microscopy and derivative analysis of filtration data collected for the two layers independently. These results provide important insights into the mechanisms governing the filtration of mRNA-LNP vaccines and therapeutics.
引用
收藏
页码:3221 / 3229
页数:9
相关论文
共 52 条
[1]   The safety of Covid-19 mRNA vaccines: a review (vol 15, 20, 2021) [J].
Anand, Pratibha ;
Stahel, Vincent P. .
PATIENT SAFETY IN SURGERY, 2021, 15 (01)
[2]  
[Anonymous], 2013, STANDARD TEST METHOD, P1, DOI [10.1520/D4972-19, DOI 10.1520/D1238-13, 10.1520/G0173-03R20.2, DOI 10.1520/E0112-13.1.4]
[3]   Downstream processing for influenza vaccines and candidates: An update [J].
B. Carvalho, Sofia ;
Peixoto, Cristina ;
T. Carrondo, Manuel J. ;
S. Silva, Ricardo J. .
BIOTECHNOLOGY AND BIOENGINEERING, 2021, 118 (08) :2845-2869
[4]   Encapsulation state of messenger RNA inside lipid nanoparticles [J].
Brader, Mark L. ;
Williams, Sean J. ;
Banks, Jessica M. ;
Hui, Wong H. ;
Zhou, Z. Hong ;
Jin, Lin .
BIOPHYSICAL JOURNAL, 2021, 120 (14) :2766-2770
[5]   Nanomaterial Delivery Systems for mRNA Vaccines [J].
Buschmann, Michael D. ;
Carrasco, Manuel J. ;
Alishetty, Suman ;
Paige, Mikell ;
Alameh, Mohamad Gabriel ;
Weissman, Drew .
VACCINES, 2021, 9 (01) :1-30
[6]   Nanotechnology for COVID-19: Therapeutics and Vaccine Research [J].
Chauhan, Gaurav ;
Madou, Marc J. ;
Kalra, Sourav ;
Chopra, Vianni ;
Ghosh, Deepa ;
Martinez-Chapa, Sergio O. .
ACS NANO, 2020, 14 (07) :7760-7782
[7]   COVID-19 Vaccine Frontrunners and Their Nanotechnology Design [J].
Chung, Young Hun ;
Beiss, Veronique ;
Fiering, Steven N. ;
Steinmetz, Nicole F. .
ACS NANO, 2020, 14 (10) :12522-12537
[8]   Fouling Behavior during Sterile Filtration of Different Glycoconjugate Serotypes Used in Conjugate Vaccines [J].
Emami, Parinaz ;
Fallahianbijan, Fatemeh ;
Dinse, Erica ;
Motevalian, Seyed Pouria ;
Conde, Brenda Carrillo ;
Reilly, Kelvin ;
Zydney, Andrew L. .
PHARMACEUTICAL RESEARCH, 2021, 38 (01) :155-163
[9]  
Folmsbee Martha, 2012, PDA J Pharm Sci Technol, V66, P161, DOI 10.5731/pdajpst.2012.00771
[10]  
Gao WW, 2013, J MATER CHEM B, V1, P6569, DOI [10.1039/c3tb21238f, 10.1039/C3TB21238F]